Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Research & Development (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Research & Development over the past 16 years, most recently at $2.1 million for Q2 2025.

  • For Q2 2025, Research & Development fell 2.68% year-over-year to $2.1 million; the TTM value through May 2025 reached $8.3 million, down 3.7%, while the annual FY2025 figure was $8.3 million, 3.7% down from the prior year.
  • Research & Development for Q2 2025 was $2.1 million at Lifecore Biomedical, Inc. \De\, up from $2.0 million in the prior quarter.
  • Over five years, Research & Development peaked at $6.7 million in Q2 2021 and troughed at $1.6 million in Q1 2021.
  • A 5-year average of $2.3 million and a median of $2.1 million in 2022 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: soared 927.23% in 2021 and later tumbled 68.33% in 2022.
  • Year by year, Research & Development stood at $1.7 million in 2021, then grew by 29.58% to $2.2 million in 2022, then decreased by 3.63% to $2.1 million in 2023, then dropped by 8.29% to $1.9 million in 2024, then grew by 9.3% to $2.1 million in 2025.
  • Business Quant data shows Research & Development for LFCR at $2.1 million in Q2 2025, $2.0 million in Q1 2025, and $1.9 million in Q4 2024.